56 results about "B-cell receptor" patented technology

The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an anti-phospholipase A2 receptor (PLA2R) autoantibody-based B cell receptor (BCR), polynucleotides encoding the CAAR, vectors comprising a polynucleotide encoding the CAAR, and recombinant cells (e.g., T cells) comprising the CAAR, wherein the CAAR comprises a PLA2R autoantigen comprising an extended cysteine rich (eCysR) domain comprising (a) a PLA2R N-terminal peptide and a cysteine rich (CysR) domain, and (b) a C-type lectin domain 7 (CTLD7). The invention also includes methods of making a genetically modified cell, e.g., a genetically modified T cell, expressing a PLA2R-CAAR wherein the expressed CAAR comprises a PLA2R autoantigen comprising an extended cysteine rich (eCysR) domain comprising (a) a PLA2R N-terminal peptide and a cysteine rich (CysR) domain, and (b) a C-type lectin domain 7 (CTLD7).

The invention relates to a TCR and / or BCR detection system based on spatial omics, and aims to solve the problems of high detection cost, low spatial resolution, incapability of accurately positioning cells and the like in the existing spatial VDJ technology. The invention provides a T cell receptor and / or B cell receptor detection system based on a spatial omics method, the system comprises: a module (1), which constructs a coding primer pool according to a VJ region sequence of TCR and / or BCR to be detected, the VJ region is formed by rearranging a V region and a J region, the coding primer pool is used for each V region and J region to be detected, and the coding primer pool is used for coding the TCR and / or BCR to be detected. Or specific coding sequences are distributed to the V region and the CDR3 region respectively; the module (2) is used for amplifying a to-be-detected VJ region of a to-be-detected tissue sample through the coding primer pool and fixing an amplification product; and the module (3) is used for positioning the amplification product by using the signal probe group and reading the coding sequence, so that the position information of the VJ region is obtained, and the sequence information of the VJ region is obtained according to the coding sequence.

An antibody against respiratory syncytial virus (RSV) and / or human metapneumovirus (HMPV) is described herein. The antibody includes binding domains from anti-idiotypic monoclonal antibodies (ai-mAbs) that bind an RSV neutralizing antibody VH3-21 / VL1-40 presented as B cell receptors (BCRs). The antibodies can be used as a vaccine to selectively elicit antibodies capable of neutralizing RSV and / or HMPV without a need for somatic mutation. The vaccines are particularly useful to treat and / or reduce the risk of RSV and / or HMPV infection in infants.

The present disclosure relates to a method for designing a personalized cancer vaccine, using a B cell-reactive neoantigen, the method comprising the steps of: receiving a peptide sequence extracted from cancer tissue and allelic sequence data of B cell receptors; calculating the preferential binding strength between amino acids in the peptide sequence and allelic sequences of B cell receptors; and calculating B cell epitope prediction scores by inputting the preferential binding strength between amino acids to a trained neural network model.

To provide a gene testing method and a gene testing kit for analyzing a variable region of a TCR or a BCR in single-cell analysis.SOLUTION: A method including a step of capturing mRNA eluted from a single cell using an RT probe immobilized on a solid-phase surface and including a common sequence, a cell identification barcode, a first molecular identification barcode, and an oligo(dT) sequence, a step of performing a reverse transcription reaction in a reverse transcription reaction solution containing a TSO using the mRNA as a template to generate cDNA having a sequence added to a 3' end, a step of degrading the mRNA, a step in which a primer for inserting a second molecular identification barcode binds to a constant region adjacent to a variable region of a TCR or a BCR and includes the second molecular identification barcode, a step of ligating cDNA extended from the primer with a ligase, a step of amplifying a fragment including the second molecular identification barcode and the variable region of the TCR or the BCR using a primer, a step of performing sequence analysis, and a step of associating sequences.SELECTED DRAWING: Figure 2

The invention is applicable to the technical field of biotechnology, and particularly relates to a primer composition for amplifying a coding sequence of a human B cell receptor heavy chain CDR3 and application of the primer composition, and two primer groups, namely a first primer group and a second primer group, are designed. The two primers are respectively used as an upstream primer and a downstream primer, and comprise at least one human IGH CDR3 upstream primer and at least one human IGH CDR3 downstream primer. The primers can be respectively combined with nucleic acid of human B cells, and a basis for researching a CDR3 region of a B cell receptor is provided. The first primer group and the second primer group are combined with the nucleic acid of the human B cell, so that the coding sequence of the heavy chain of the human B cell receptor is effectively enriched, part of pseudogenes are contained, the amplification efficiency of the heavy chain CDR3 library of the human B cell receptor can be improved, and the deep research on immune response of the human B cell is promoted.

The present invention relates to genetically engineered B cells wherein the B cells express and bear chimeric B cell receptors on their surface, and wherein the genetically engineered B cells further express and secrete antibodies or cytokines.

This present disclosure relates to systems, methods, and compositions useful for profiling T cell receptor (TCR) and B cell receptor (BCR) repertoire using next-generation sequencing (NGS) methods. The present disclosure also relates to systems and methods for diagnosing, treating, or predicting infection, disease, medical conditions, therapeutic outcome, or therapeutic efficacy based on the TCR / BCR profile data from a subject in need thereof.

The invention provides a rabbit-source BCR sequence primer group based on high-throughput single cell V (D) J sequencing and application of the rabbit-source BCR sequence primer group. The primer group comprises a specific nested PCR (Polymerase Chain Reaction) primer pair (the sequence is as shown in SEQ ID NO.1-12) aiming at a rabbit BCR heavy chain (IgA / IgE / IgG / IgM) and a light chain (IgK / IgL). Through microfluid single-cell separation, nested PCR amplification and high-throughput sequencing, the naturally paired rabbit BCR full-length V (D) J sequence can be efficiently obtained. According to the rabbit-derived BCR sequence sequencing primer provided by the invention, B cell receptor library information of different tissue sources can be quickly and efficiently obtained. According to the method, paired antibody sequence information can be specifically obtained, B cell response diversity after rabbit immunization vaccine or pathogen infection can be better known, and important data support is provided for design, optimization, effect evaluation and the like of biological products.

The present disclosure provides methods, compositions, kits, and systems useful in the determination and evaluation of the immune repertoire using genomic DNA from a biological sample. In one aspect, target-specific primer panels provide for the effective amplification of sequences of T cell receptor and / or B cell receptor chains with improved sequencing accuracy and resolution over the repertoire. Nucleic acid sequences of variable regions associated with the immune cell receptor are determined to effectively portray clonal diversity of a biological sample and / or differences associated with the immune cell repertoire of a biological sample.

This document provides methods and materials for assessing and / or treating subjects (e.g., humans) suspected of having cancer. For example, this document provides methods and materials for a nucleic acid sequence analysis which can determine a sequence of B cell receptor. In some cases, determining a sequence of B cell receptor (and, optionally, identifying the presence of one or more mutations and / or identifying the presence of aneuploidy) in DNA (e.g., cell-free DNA (cfDNA)) in a fluid sample (e.g., a cerebrospinal fluid sample) obtained from a subject (e.g., a human subject such as a human suspected of having cancer) can be used to identify the subject as having cancer.

Provided herein are assays and methods of assessing vaccine preparations, and engineered B cell receptors (BCR) and engineered B cell lines used in such assays and methods.

Provided are: an agent for damaging and / or removing cell receptor (BCR)-expressing cells; and a therapeutic agent and a pharmaceutical composition for autoimmune disease each containing the agent. The agent for damaging and / or removing BCR-expressing cells comprises: a group capable of selectively binding to at least one selected from the group consisting of a BCR recognizing a self-antigen and an antibody recognizing the self-antigen; and a substance having a cytotoxic group.

The present specification discloses a composition, a system, and a method for predicting or diagnosing Alzheimer's disease, comprising a detecting agent of a B cell receptor clonotype specific to an Alzheimer's disease patient, and the composition according to one aspect of the present invention has an excellent effect in predicting or diagnosing Alzheimer's disease by simply using peripheral blood mononuclear cells isolated from a subject, in addition to methods such as MRI and PET scans using radioactive substances, by comprising a detecting agent of a B cell receptor (BCR) clonotype specific to an Alzheimer's disease patient.

The invention includes a chimeric autoantibody receptor (CAAR) specific for anti-acetylcholine receptor (AChR) B cell receptor (BCR), compositions comprising the CAAR, polynucleotides encoding the CAAR, vectors comprising a polynucleotide encoding the CAAR, and recombinant cells, e.g., T cells comprising the CAAR.

The present disclosure relates generally to methods of uniquely labeling or barcoding molecules within immune cells such as B cells, or within nuclei derived therefrom. The present disclosure also relates to kits for uniquely labeling molecules within immune cells such as B cells, or within nuclei derived therefrom. In particular, the methods and kits may relate to the labeling of RNAs and / or cDNA encoding B cell receptors (BCRs) within such cells or nuclei.

Methods and systems are described herein for generating engineered B cells with modified immunoglobulin genes. The modified immunoglobulin genes encode modified immunoglobulins that can have high affinity for antigens, including antigens that are variable such the types of antigens on various pathogens that can escape mammalian immune responses.

The invention provides an EBV susceptible 293T cell capable of simultaneously expressing an epidermal cell receptor EphA2 and a cleavage replication key protein RTA, and an EBV susceptible BJAB cell capable of simultaneously expressing a B cell receptor CD21 and a cleavage replication key protein ZTA, so that the infectivity of the cells on EBV is remarkably improved. The EBV infection titer of the cell line disclosed by the invention is more than three times that of normal control under the same condition. The EBV susceptible cells are of great significance to research of EBV infection mechanisms, screening of antiviral drugs and research and development of vaccines.

The present disclosure relates to target sequencing of T and B cell receptor gene rearrangements at the DNA level and using this technology to detect and quantify lymphoid malignant T or B cells (minimal residual disease, MRD) during and after therapy.

The present disclosure relates to target sequencing of T and B cell receptor gene rearrangements at the DNA level and using this technology to detect and quantify lymphoid malignant T or B cells (minimal residual disease, MRD) during and after therapy.

The present invention provides a genetic test method and a genetic test kit for immune cells in blood. Specifically, the present invention provides a genetic test method and a genetic test kit for analyzing a variable region of a T cell receptor (TCR) or a B cell receptor (BCR) in a single cell analysis technique.

Disclosed herein include systems, methods, compositions, and kits for immune repertoire profiling. There are provided, in some embodiments, primer panels enabling the determination of the nucleotide sequence of the complete variable region of nucleic acids encoding mouse B cell receptor (BCR) and T cell receptor (TCR) polypeptides. In some embodiments, the method comprises single cell transcriptomic analysis.

The present disclosure provides methods, compositions, kits, and systems that can be used to assay and evaluate an immune repertoire. In one aspect, a set of target-specific primers provides efficient amplification of the sequences of B cell receptor chains with improved sequencing accuracy and resolution relative to the repertoire. Variable regions associated with immune cell receptors are resolved to effectively delineate the clonal diversity of a biological sample and / or differences associated with the immune cell repertoire of a biological sample.

This invention is directed to genetically engineered B cells, wherein the B cell expresses and bears on its surface a chimeric B cell receptor, and wherein the genetically engineered B cell further expresses and secretes an antibody or cytokine.

The application discloses a hepatitis B surface antigen specific B cell receptor gene knock-in mouse model, and establishes a hepatitis B virus surface antigen (HBsAg) specific B cell receptor (BCR) gene knock-in mouse model, wherein 70-90% of B cells of the mouse can specifically recognize HBsAg, and differentiate into germinal center B cells and plasma cells. Therefore, the model can be used for basic research on hepatitis B antiviral humoral immune response and tolerance mechanism, and can also be used for application research on development of drugs and vaccines for breaking HBsAg immune tolerance. In summary, the establishment of the model lays a solid foundation for development of a functional cure immune means for hepatitis B.

This invention provides EBV-susceptible 293T cells that simultaneously express the epidermal cell receptor EphA2 and the key protein RTA for lysis and replication, and EBV-susceptible BJAB cells that simultaneously express the B cell receptor CD21 and the key protein ZTA for lysis and replication, significantly enhancing the infectivity of these cells for EBV. The EBV infection titer of the cell lines of this invention is more than three times that of the normal control under the same conditions. These EBV-susceptible cells are of great significance for studying the mechanism of EBV infection, screening antiviral drugs, and developing vaccines.

Disclosed herein is a pipeline to identify variable chains (VCR), which encompass T cell receptors (TCRs) and B cell receptors (BCRs), that recognize epitopes in their low affinity using a bioinformatic statistical method with 10× data that encompasses both preprocessing and identification of antigen-specific VCRs. Also disclosed are methods for treating subjects having viral infections or cancer, the methods comprising administering antibodies from B cells transduced with antigen-specific BCRs and / or modified allogenic T cells transduced with antigen-specific TCRs identified through use of the pipeline.

To provide a polypeptide capable of inducing an anti-IgE antibody extremely efficiently in vivo.SOLUTION: The present invention provides a vaccine composition capable of inducing production of an antibody against IgE, the vaccine composition containing a complex of a T-cell receptor antigen peptide and a B-cell receptor antigen peptide, wherein the B-cell receptor antigen peptide includes an amino acid sequence represented by any one of SEQ ID NOs: 20-22.SELECTED DRAWING: None

The present disclosure relates to methods for testing the health of a subject's immune system and treating the subject based on the condition of the immune system. In particular, disclosed herein is a method comprising the steps of obtaining a sample of blood from the subject, reverse transcribing DNA from RNA in the sample; amplifying all seven chains of T and B cell receptors in the DNA sample using multiplex PCR to form amplicons; sequencing the amplicons to generate a sequencing library; identifying nodetypes, clonotypes, v genes, d genes, and j genes and corresponding read counts in the sequencing library; performing the foregoing steps using two or more healthy samples to form a consensus reference pool; identifying the number of nodetypes associated with each V gene sequence in the consensus reference pool and in the subject's sequencing library; comparing the number of nodetypes for each V gene in the consensus reference pool and the subject's sequencing library; and treating the subject if the number of nodetypes is significantly less than the number of nodetypes for V genes in the consensus reference pool. The disclosed method is able to identify gaps in an individual's immune system and treat that individual to improve the diversity of the individual's immune response.

Methods and systems are provided to obtain a clinically meaningful characterization of T cell receptor (TCR) or B cell receptor (BCR) repertoire using cell-free-DNA or immune cell-derived DNA.